🇺🇸 FDA
Patent

US 11326156

Modified caspase-9 polypeptides and methods of use thereof

granted A61KA61K2239/23A61K31/7088

Quick answer

US patent 11326156 (Modified caspase-9 polypeptides and methods of use thereof) held by Allogene Therapeutics, Inc. expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Allogene Therapeutics, Inc.
Grant date
Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2239/23, A61K31/7088, A61K35/17, A61K38/4873